Counterfeit Drug and related drug adulteration has become a global menace. Lack of policy consistency, opulence and control of Gray market and inefficient Pharmaceutical Supply Chain and related security challenges has been the buzz across the countries to streamline the distribution system . A comprehensive serialization road map is being enacted by DQSA (Drug Quality & Security Act) for Drug manufacturers, distributors, re-packagers and also third-party logistics providers to enforce the transparency in the drug supply chain. FDA will continue working with industry to effectively implement a streamlined supply chain which will benefit all genuine partners. Serialization will addresses many challenges in global supply of drugs enacting control, monitoring and also authenticating by sharing data across the supply chain.